Source comparison
Tesamorelin Differs From Egrifta SV: Formulation & Dosing Comparison
Active Molecule 44-amino-acid GHRH analogue with trans-3-hexenoic acid modification Tesamorelin 1mg per vial Tesamorelin 2mg per vial Identical peptide structure across all formulations. No pharmacological difference Therapeutic Dose 2mg subcutaneous daily Two
This comparison does not assign a generated winner or score.
- Active Molecule
- 44-amino-acid GHRH analogue with trans-3-hexenoic acid modification
- Tesamorelin 1mg per vial
- Tesamorelin 2mg per vial
- Identical peptide structure across all formulations. No pharmacological difference
- Therapeutic Dose
- 2mg subcutaneous daily
- Two 1mg vials reconstituted separately, then combined
- One 2mg vial reconstituted once
- Same daily dose; SV reduces preparation steps by 50%
- Reconstitution Volume
- 2.2mL sterile water per 1mg peptide
- 2.2mL per vial × 2 vials = 4.4mL total before injection
- 2.2mL per vial, used immediately
- SV eliminates the step of combining two reconstituted solutions
- Storage Pre-Reconstitution
- 2–8°C refrigerated
- No difference. Both require cold chain integrity
- Storage Post-Reconstitution
- Use immediately; no approved storage
- Discard unused portion
- Neither formulation is preservative-stabilised for multi-dose use
- FDA Approval Year
- N/A (molecule, not product)
- 2010 (for HIV-associated VAT reduction)
- 2018 (bioequivalence submission, same indication)
- SV approval based on PK equivalence, not new efficacy trials
- Mean VAT Reduction (26 weeks)
- 15.2% in pivotal trials
- 15.2% vs 1.8% placebo
- Bioequivalent to original Egrifta
- Same therapeutic effect. Formulation doesn't alter outcome
- Adherence Impact
- N/A
- 60% maintained ≥80% adherence at 24 weeks
- 78% maintained ≥80% adherence at 24 weeks
- Single-vial formulation improves compliance through reduced preparation burden